Eva J Gordon
Overview
Explore the profile of Eva J Gordon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barzi A, Weipert C, Espenschied C, Raymond V, Wang-Gillam A, Nezami M, et al.
Front Oncol
. 2024 Feb;
14:1339302.
PMID: 38406801
Purpose: Despite accumulating data regarding the genomic landscape of pancreatic ductal adenocarcinoma (PDAC), olaparib is the only biomarker-driven FDA-approved targeted therapy with a PDAC-specific approval. Treating (HER2)-amplified PDAC with anti-HER2...
2.
Al-Aloosi M, Prechtl A, Chatterjee P, Bernard B, Kemp C, Rosati R, et al.
Front Oncol
. 2024 Jan;
13:1267650.
PMID: 38239650
Patients presenting with stage 4 ovarian carcinoma, including low-grade serous disease, have a poor prognosis. Although platinum-based therapies can offer some response, these therapies are associated with many side effects,...
3.
Parker D, Zambelli J, Lara M, Wolf T, McDonald A, Lee E, et al.
Front Oncol
. 2023 May;
13:1192792.
PMID: 37188199
Despite decades of research and clinical trials, metastatic castration-resistant prostate cancer (mCRPC) remains incurable and typically fatal. Current treatments may provide modest increases in progression-free survival but can come with...
4.
Gordon E, Parker D, Barth K, Pena J, Elvin J, DeLeon T, et al.
Case Rep Oncol
. 2018 Jul;
11(2):399-403.
PMID: 30022943
Mutations or other alterations in the gene have been implicated in a variety of malignancies - most commonly thyroid, but also chronic myelomonocytic leukemia, acute myeloid leukemia, and lung, breast,...
5.
Mills D, Gomberawalla A, Gordon E, Tondre J, Nejad M, Nguyen T, et al.
PLoS One
. 2016 Apr;
11(4):e0150653.
PMID: 27073976
Background: The human breast comprise several ductal systems, or lobes, which contain a small amount of fluid containing cells, hormones, proteins and metabolites. The complex physiology of these ducts is...
6.
Mahoney M, Gordon E, Rao J, Jin Y, Hylton N, Love S
Clin Breast Cancer
. 2013 May;
13(4):280-6.
PMID: 23664819
Introduction: Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer wherein malignant cells are confined within a ductal lobular unit. Although less than half the cases of DCIS will...
7.
Love S, Zhang W, Gordon E, Rao J, Yang H, Li J, et al.
Cancer Prev Res (Phila)
. 2012 Nov;
6(1):51-8.
PMID: 23169924
Preclinical data have shown the potential of the intraductal administration of chemotherapy for breast cancer prevention. Direct translation of this work has been stymied by the anatomical differences between rodents...
8.
Mills D, Gordon E, Casano A, Lahti S, Nguyen T, Preston A, et al.
J Physiol Biochem
. 2011 Oct;
67(4):621-7.
PMID: 21983803
The physiology of the nonlactating human breast likely plays a key role in factors that contribute to the etiology of breast cancer and other breast conditions. Although there has been...
9.
10.
Mowery P, Yang Z, Gordon E, Dwir O, Spencer A, Alon R, et al.
Chem Biol
. 2004 May;
11(5):725-32.
PMID: 15157883
L-selectin is a leukocyte cell-surface protein that facilitates the rolling of leukocytes along the endothelium, a process that leads to leukocyte migration to a site of infection. Preventing L-selectin-mediated rolling...